Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert video report on Breast Cancer from AACR 2020

Reporting remotely on findings presented at AACR 2020 Virtual Meeting, Lajos Pusztai comments on important breast cancer studies.

He firstly presents results from the I-SPY 2 trial evaluating the addition of olaparib to immune checkpoint inhibitors in high-risk, HER2-negative, locally advanced breast cancer. He then comments on two presentations of the EMBRACA trial on the effect of talazoparib on overall survival in patients with advanced, HER2-negative breast cancer with a germline BRAC1/2 mutation, and on the impact of tumour BRCA zygosity and genomic loss-of-heterozygosity as a biomarker for patient selection.

Abstracts:
• CT011 - Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL (Lajos Pusztai, USA)
• CT071 - Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial (Jennifer Litton, USA)
• CT072 - Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2−) advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA1/2) mutation (Lida Mina, USA)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings